| Literature DB >> 35018558 |
Katie Glover1, Essyrose Mathew1, Giulia Pitzanti1, Erin Magee1, Dimitrios A Lamprou2.
Abstract
The treatment strategy required for the effective healing of diabetic foot ulcer (DFU) is a complex process that is requiring several combined therapeutic approaches. As a result, there is a significant clinical and economic burden associated in treating DFU. Furthermore, these treatments are often unsuccessful, commonly resulting in lower-limb amputation. The use of drug-loaded scaffolds to treat DFU has previously been investigated using electrospinning and fused deposition modelling (FDM) 3D printing techniques; however, the rapidly evolving field of bioprinting is creating new opportunities for innovation within this research area. In this study, 3D-bioprinted scaffolds with different designs have been fabricated for the delivery of an antibiotic (levoflocixin) to DFU. The scaffolds were fully characterised by a variety of techniques (e.g. SEM, DSC/TGA, FTIR, and mechanical characterisation), demonstrating excellent mechanical properties and providing sustained drug release for 4 weeks. This proof of concept study demonstrates the innovative potential of bioprinting technologies in fabrication of antibiotic scaffolds for the treatment of DFU.Entities:
Keywords: Bioprinting; Diabetes mellitus; Diabetic foot ulcer; Drug delivery; Levofloxacin; Wound healing
Year: 2022 PMID: 35018558 DOI: 10.1007/s13346-022-01115-8
Source DB: PubMed Journal: Drug Deliv Transl Res ISSN: 2190-393X Impact factor: 4.617